Prevalence of visual impairment and associated risk factors: a cross-sectional community-based study among children and adolescents in Ghana - Top-Institutions - MDSpire

Prevalence of visual impairment and associated risk factors: a cross-sectional community-based study among children and adolescents in Ghana

  • By

  • Josephine Ampomah Boateng

  • Werner Eisenbarth

  • Sylvester Kyeremeh

  • Albert Kwadjo Amoah Andoh

  • Isaiah Osei Duah Junior

  • Debora Abena Baidoo

  • Sylvia Agyekum

  • Daniel Boateng

  • Emmanuel Antwi

  • Kwadwo Owusu Akuffo

  • May 20, 2026

  • 0 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, Maryland

    Key Differentiators

    • Ophthalmology

  • #2

    UCSF Francis I. Proctor Foundation for Research in Ophthalmology
    UCSF Francis I. Proctor Foundation for Research in Ophthalmology

    San Francisco, California

    Key Differentiators

    • Ophthalmology

  • #3

    Levy Mwanawasa Medical University
    Levy Mwanawasa Medical University

    Lusaka, Zambia

    Key Differentiators

    • Ophthalmology

Original Source(s)

Prevalence of visual impairment and associated risk factors: a cross-sectional community-based study among children and adolescents in Ghana

  • by Josephine Ampomah Boateng, Werner Eisenbarth, Sylvester Kyeremeh, Albert Kwadjo Amoah Andoh, Isaiah Osei Duah Junior, Debora Abena Baidoo, Sylvia Agyekum, Daniel Boateng, Emmanuel Antwi, Kwadwo Owusu Akuffo

  • May 20, 2026

Related Content

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

  • May 25, 2026

  • 3 min